On July 30, the FDA posted new and revised versions of the following Import Alerts on the detention without physical examination of:
The Bureau of Industry and Security is seeking public comments on an information collection related to Section 232 national security adjustments for imports, it said in a Federal Register notice. The data collection relates to presidential proclamations 10895 and 10896, which require the Department of Commerce secretary to establish a process for including additional derivative aluminum and steel articles within the Section 232 tariffs for steel and aluminum. BIS said the agency is collecting data as part of broader efforts by the commerce secretary to conduct investigations on the effects on U.S. national security of importing an article. Comments are due by Sept. 30.
Sen. Tim Kaine, D-Va., Senate Minority Leader Chuck Schumer of New York, Senate Finance Committee ranking member Ron Wyden of Oregon and Sen. Jeanne Shaheen, D-N.H., made a joint announcement July 31 that they will request a vote to end the new International Emergency Economic Powers Act declaration for Brazil, that underpins an additional 40% tariff on a portion of Brazil's exports.
Sens. Tim Kaine, D-Va., and Rand Paul, R-Ky., expressed frustration this week with the potential impact on the U.S. spirits industry from the Trump administration's tariffs, saying they will continue fighting to repeal duties introduced through both the International Emergency Economic Powers Act and Section 232.
On the eve of more tariff hikes, four prominent Senate Democrats decried what they said were so-called deals -- or, as Senate Minority Leader Chuck Schumer put it, "a raw deal for the American people."
President Donald Trump, after softening his tone on India with reporters earlier in the day, posted angrily about India and its purchases of Russian oil at midnight on July 31.
President Donald Trump sent letters to AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, EMD Serono, Genentech, Gilead, GSK, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pfizer, Regeneron and Sanofi, posting several of them online, telling them they should, within 60 days, set prices for Medicaid at the same level as the cheapest price their drugs are sold in a developed country; contract that when new drugs are launched, Medicaid, Medicare and private insurers all get that global low price; and allow direct-to-consumer sales for high-volume drugs, as long as those sales are at the same price as to insurers.
CBP issued the following releases on commercial trade and related matters:
A listing of recent Commerce Department antidumping and countervailing duty messages posted on CBP's website July 30, along with the case number(s) and CBP message number, is provided below. The messages are available by searching for the listed CBP message number at CBP's ADCVD Search page.
CBP will be watching for entries that don't fully calculate the duty value of merchandise that falls under Section 232 duties for copper and intensive copper derivatives products, according to a cargo systems message offering guidance on the tariff that was announced earlier this week (see 2507300061). The Section 232 tariff calls for a 50% ad valorem duty on all imports of semi-finished copper products and intensive copper derivative products from all countries.